Key Moments
#103 – Looking back on the first 99 episodes: Strong Convictions, Loosely Held
Peter Attia MDKey Moments
Peter Attia reflects on changes in his views on Metformin, Rapamycin, and more. He emphasizes 'strong convictions, loosely held' as key to learning.
Key Insights
The core principle of 'strong convictions, loosely held' is crucial for intellectual growth and adapting to new information, especially in science and medicine.
Peter Attia has evolved his perspective on Metformin, now reserving it for those with clear metabolic needs rather than as a general longevity agent, due to concerns about mitochondrial toxicity.
Rapamycin is viewed with increasing interest as a potential longevity agent, but its optimal dosing and long-term effects in healthy individuals still require more research and personalized biomarker assessment.
Embracing new practices like having a dog or consistently pursuing mastery in activities like archery, even if initially reluctant, offers significant, often intangible, life benefits.
Zone 2 training has become a cornerstone of Peter Attia's exercise routine, recognized for its substantial metabolic and neurotrophic benefits, and its compatibility with learning.
The importance of the deadlift has been re-evaluated, shifting from a heavy lift to a diagnostic tool for assessing fundamental movement mechanics crucial for everyday life and spinal health.
A shift in thinking regarding generic drugs has occurred, emphasizing the need for careful selection and prioritizing branded medications in certain cases due to potential variability.
Omega-3 fatty acids, particularly EPA, are increasingly recognized as potent therapeutic agents for cardiovascular health, with a potential need for higher target intake levels.
Developing the skill of saying 'no' is essential for managing time and energy, allowing focus on what truly matters and preventing burnout from overcommitment.
The podcast itself has been a journey of learning and adaptation, transforming from a perceived burden to a valuable platform for exploration and knowledge sharing.
THE EVOLVING THOUGHT PROCESS
The podcast episode centers on the concept of 'strong convictions, loosely held,' a philosophy Peter Attia adopts to navigate the dynamic nature of scientific and medical understanding. This approach involves forming firm beliefs based on available evidence but remaining open to revising them as new data emerges. Attia contrasts this with rigid adherence to outdated ideas, emphasizing that adaptability and a willingness to be wrong are hallmarks of scientific progress and personal growth. This retrospective, prompted by the 100th episode milestone, explores specific instances where his views have shifted significantly over the podcast's run.
METFORMIN: FROM LONGEVITY PROMISE TO CAUTIOUS USE
Initially, Peter Attia prescribed Metformin for its perceived benefits in reducing cancer mortality and improving survival, even in non-diabetic individuals. His conviction began to waver after noticing elevated lactate levels, a potential indicator of mitochondrial stress, which he began measuring during zone 2 training. This discovery led him to question Metformin's utility for metabolically healthy individuals, suspecting it might be a mild mitochondrial toxin. Consequently, he stopped taking it and now reserves prescriptions for patients with clear metabolic issues, viewing it less as a universal longevity drug and more as a targeted intervention.
RAPAMYCIN: A GROWING INTEREST WITH CAUTION
Rapamycin and its analogues have been an area of keen interest for Attia for many years, particularly after a study showed its potential to augment immune response in older adults. While acknowledging its immunosuppressive effects in organ transplantation, he finds the data supporting its potential longevity benefits compelling, especially from animal studies. However, the lack of clear biomarkers for efficacy and safety in humans makes dosing challenging. Attia cycles Rapamycin, emphasizing the need for continued research into optimal protocols and personalized monitoring, while maintaining a high conviction in its potential.
THE UNEXPECTED JOYS OF OWNERSHIP: DOGS AND MASTERING SKILLS
Attia recounts his initial reluctance to get a dog, citing a lack of bandwidth, but ultimately caving to his family's desire. The experience of raising their puppy, Molly, has been more demanding than anticipated but has also brought unexpected emotional rewards. This mirrors his journey with archery, an activity he initially pursued for its technical challenge but now deeply appreciates for its meditative qualities and the constant pursuit of improvement. He highlights the value of embracing commitments, even those that initially seem daunting, as they often yield profound, intangible benefits.
RECALIBRATING EXERCISE: ZONE 2 AND THE DEADLIFT DIAGNOSTIC
Central to Attia's evolving fitness philosophy is a renewed emphasis on Zone 2 training, which he had previously neglected in favor of high-intensity efforts. Influenced by experts like Inigo San Millan, he now dedicates significant time to low-intensity aerobic activity, recognizing its crucial role in metabolic health, mitochondrial function, and neurotrophic factor release. Similarly, his perspective on the deadlift has transformed; it's no longer about maximal weight but serves as a precise diagnostic tool to assess and refine fundamental movement patterns, promoting spinal health and functional fitness for daily activities.
PHARMACEUTICALS AND PREVENTION: REVISITING OLD BELIEFS
Attia discusses several areas where his beliefs have been challenged. He now questions the efficacy of baby aspirin for DVT prevention during flights, finding little evidence to support it and more promising evidence for supplements like Flight Tab and Nattokinase. His views on generic drugs have also shifted dramatically following a conversation with Kathryn Dennison; he now advocates for careful selection, sometimes prioritizing branded medications due to concerns about bioavailability and manufacturing quality, a significant departure from his previous stance that generics were universally equivalent and cheaper.
THE STRATEGIC VALUE OF SAYING 'NO' AND OMEGA-3S
The ability to decline requests has become a practiced skill for Attia, crucial for managing his demanding schedule and focusing on priorities. He recognizes that saying 'yes' to one thing inherently means saying 'no' to countless others. This principle is also applied to his evolving understanding of Omega-3 fatty acids, particularly EPA and DHA, which he now views as potent therapeutic agents rather than simple supplements. While still exploring the nuances of Omega-6 PUFAs, his confidence in the necessity of adequate EPA/DHA intake has grown, potentially requiring higher levels than previously recommended.
THE PODCAST AS A LEARNING LABORATORY
Attia reflects on his initial apprehension about starting 'The Drive' podcast, fearing the immense workload. However, the experience has been surprisingly enjoyable and educational, largely due to his dedicated team who handle the heavy lifting of production. He particularly cherishes episodes with technical depth from guests like Rick Johnson and Keith Flaherty, as well as deeply personal interviews with individuals like Damon Hill. The podcast has evolved into a powerful tool for learning, constantly expanding his list of potential guests and topics, solidifying his belief in its long-term viability and his own continuous improvement as a host.
Mentioned in This Episode
●Supplements
●Products
●Books
●Studies Cited
●People Referenced
Common Questions
This philosophy emphasizes maintaining strong beliefs and making decisions based on them, but remaining open and willing to change those convictions when presented with new information or evidence. It's a mindset crucial for scientific and medical progress.
Topics
Mentioned in this video
An expert on aging and longevity, who was interviewed on the podcast and discussed the potential of Metformin.
An expert interviewed on the podcast regarding Rapamycin and mTOR.
An expert interviewed on the podcast alongside David Sabatini about Rapamycin and mTOR.
Author of the upcoming book 'Malignant', which discusses public health policy and cancer.
Co-founder of Basecamp, interviewed on the podcast about the importance of saying no and protecting one's time.
Athlete whose favorite Super Bowl ring is often stated as 'the next one', used as an analogy for Peter Atia's favorite podcast episode potentially being the next one.
An investor known for his disciplined schedule and focus on reading, used as an example of guarding time effectively.
Author mentioned for his exceptional writing ability, particularly in 'The Emperor of All Maladies'.
Hockey player, highlighted as someone Peter Atia would like to interview for an in-depth discussion about the Edmonton Oilers.
Host of The Tim Ferriss Show, mentioned for having an episode about the importance of saying no.
An interviewee whose technical content Peter Atia found so valuable he has revisited the episode multiple times.
An interviewee whose technical content Peter Atia found so valuable he has revisited the episode multiple times.
An interviewee whose discussion Peter Atia felt would greatly benefit listeners.
Collaborator and co-host on The Drive podcast, instrumental in preparing for episodes.
Guest on the podcast who discussed omega-3 fatty acids, influencing Peter Atia's views on EPA, DHA, and omega-6.
Former Formula 1 driver, interviewed on the podcast; Peter Atia found the experience special and moving.
Author of 'Stillness is the Key', interviewed on the podcast; his work is highly influential for Peter Atia.
Investor, often discussed alongside Charlie Munger for his disciplined approach to time management.
Guest on the podcast whose discussion on generic drugs significantly changed Peter Atia's perspective.
A book by Siddhartha Mukherjee, noted for its depth and quality, which Peter Atia reread.
A book by Ryan Holiday that Peter Atia has reread multiple times and finds profoundly captivating, emphasizing its importance for well-being.
Another book by Ryan Holiday, which Peter Atia is a huge fan of.
An upcoming book by Vinay Prasad about public health policy and cancer.
A book by Ryan Holiday, part of a series, that Peter Atia also appreciates.
A drug Peter Atia has been increasingly interested in for many years, for its potential longevity benefits, noting a turning point with a 2014 study on its effect on immune system vaccination response.
A pharmaceutical-grade EPA drug, mentioned as an example of the potency of EPA for cardiovascular health.
A drug initially taken by Peter Atia for its potential longevity and cancer benefits, but later re-evaluated due to concerns about mitochondrial toxicity and elevated lactate levels.
A Rapamycin analogue mentioned in the context of a 2014 study that showed augmented vaccination strength in healthy subjects.
A supplement that was found to have evidence for preventing Deep Vein Thrombosis (DVT) during flights, contrasting with the inefficacy of baby aspirin.
Peter Atia's new puppy, adopted four weeks prior to the recording, who has visually impaired and is the runt of her litter.
More from Peter Attia MD
View all 258 summaries
135 min381‒Alzheimer’s disease in women: how hormonal transitions impact the brain, new therapies, & more
9 minIs Industrial Processing the Real Problem With Seed Oils? | Layne Norton, Ph.D.
13 minCooking with Lard vs Seed Oils | Layne Norton, Ph.D.
146 min380 ‒ The seed oil debate: are they uniquely harmful relative to other dietary fats?
Found this useful? Build your knowledge library
Get AI-powered summaries of any YouTube video, podcast, or article in seconds. Save them to your personal pods and access them anytime.
Try Summify free